company background image
TRDA logo

Entrada Therapeutics NasdaqGM:TRDA Stock Report

Last Price

US$16.98

Market Cap

US$596.3m

7D

-4.9%

1Y

0.2%

Updated

22 Jul, 2024

Data

Company Financials +

Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$596.3m

TRDA Stock Overview

A clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.

TRDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Entrada Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Entrada Therapeutics
Historical stock prices
Current Share PriceUS$16.98
52 Week HighUS$18.17
52 Week LowUS$10.75
Beta-0.26
11 Month Change14.34%
3 Month Change31.73%
1 Year Change0.18%
33 Year Changen/a
5 Year Changen/a
Change since IPO-29.10%

Recent News & Updates

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

Recent updates

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Shareholder Returns

TRDAUS BiotechsUS Market
7D-4.9%0.2%-2.1%
1Y0.2%12.5%19.0%

Return vs Industry: TRDA underperformed the US Biotechs industry which returned 12.5% over the past year.

Return vs Market: TRDA underperformed the US Market which returned 19% over the past year.

Price Volatility

Is TRDA's price volatile compared to industry and market?
TRDA volatility
TRDA Average Weekly Movement7.8%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: TRDA's share price has been volatile over the past 3 months.

Volatility Over Time: TRDA's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016160Dipal Doshiwww.entradatx.com

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

Entrada Therapeutics, Inc. Fundamentals Summary

How do Entrada Therapeutics's earnings and revenue compare to its market cap?
TRDA fundamental statistics
Market capUS$596.34m
Earnings (TTM)US$23.49m
Revenue (TTM)US$162.87m

25.4x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRDA income statement (TTM)
RevenueUS$162.87m
Cost of RevenueUS$105.39m
Gross ProfitUS$57.48m
Other ExpensesUS$34.00m
EarningsUS$23.49m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.67
Gross Margin35.29%
Net Profit Margin14.42%
Debt/Equity Ratio0%

How did TRDA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.